Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  therapeutic autologous lymphocytes
Find trials that include:  Any drugs shown
Results 1-23 of 23 for your search:
Start Over
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 1409.00, NCI-2010-00130, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 80 and under
Trial IDs: MULTIPRAT, NCI-2012-00636, 23637-MULTIPRAT, H-23637, NCT00840853
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
Laboratory-Treated Therapeutic Autologous Lymphocytes in Treating Patients With Advanced Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: UPCC 01411, NCI-2011-00960, NCT01352286
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
Tumor Infiltrating Lymphocytes after Chemotherapy in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0260, NCI-2013-01506, 110260, 11-C-0260E, P11855, NCT01468818
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-1055, NCI-2014-01040, R1301, SU2C-AACR-OT 1012, NCT02027935
CART-19 Cells in Treating Patients With Chemotherapy Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC13413, NCI-2014-00173, 818607, NCT02030834
Laboratory-Treated T-Cells in Treating Patients With Chemotherapy-Resistant or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 21413, NCI-2014-00172, UPCC 21413, NCT02030847
Basiliximab in Treating Patients with Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Phase: Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: Pro00000581, NCI-2011-03848, CDR0000579683, SPORE Project 3, DUMC-PRO00000581, NCT00626483
Vaccine Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme Recovering from Therapeutic Temozolomide-Induced Lymphopenia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00003877, NCI-2011-03843, CDR0000589624, DUMC-8108-07-1R1, DUMC-PRO00003877, NCI-09-C-0038, NCT00639639
Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: CHARKALL, NCI-2012-00845, H-23574, H-23574-CHARKALL, NCT00881920
Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: H-29617, NCI-2013-01016, GRALE, NCT01555892
Activated Natural Killer Cells with or without Recombinant Interleukin-15 in Treating Younger Patients with Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 25
Trial IDs: 13-C-0152, NCI-2013-01215, 09-25-0099, 130152, P9493_A06PAMDREVW01, 9493, NCT01875601
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients with Metastatic Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RENAL0027, NCI-2013-01688, NCT01943188
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CM-14-001, NCI-2015-00502, 5R44HL099217-03, NCI-2015-00503, NCT02203825
Expanded Natural Killer Cell Infusion in Treating Younger Patients with Recurrent/Refractory Brain Tumors
Phase: Phase I
Type: Treatment
Age: 21 and under
Trial IDs: 2013-0765, NCI-2014-02677, NCT02271711
Lymphocyte Infusion in Treating Patients With Newly Diagnosed High-Grade Glioma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: J11162, NCI-2012-01332, NA_00068991, NCT01653834
Start Over